Early Births Down With 17α-Hydroxyprogesterone Caproate

Share this content:
Early Births Down With 17α-Hydroxyprogesterone Caproate
Early Births Down With 17α-Hydroxyprogesterone Caproate

MONDAY, Oct. 17, 2016 (HealthDay News) -- For women with a prior preterm birth, cerclage plus 17α-hydroxyprogesterone caproate is associated with a significant reduction in delivery at less than 24 weeks of gestation compared with cerclage alone, according to a study published in the November issue of Obstetrics & Gynecology.

Bethany Stetson, M.D., from the Ohio State Wexner Medical Center in Columbus, and colleagues identified women with transvaginal cerclage placement and a prior delivery between 16 and 36 weeks of gestation over a 10-year period. Outcomes, including the primary outcome of delivery at less than 24 weeks of gestation, were compared for women with a cerclage alone (171 women) and those with cerclage plus 17α-hydroxyprogesterone caproate (89 women).

The researchers found that delivery at less than 24 weeks of gestation occurred in 6 and 16 percent of women receiving cerclage plus 17α-hydroxyprogesterone caproate and cerclage alone (odds ratio, 0.31). The combined treatment group had a 73 percent reduction in delivery compared with the cerclage-alone group after the researchers controlled for indomethacin use, prior cerclage, and loop electrosurgical excision procedure-cold knife cone and cerclage surgery (adjusted odds ratio, 0.26).

"Women receiving transvaginal cerclage plus 17α-hydroxyprogesterone caproate had a 69 percent relative reduction in delivery at less than 24 weeks of gestation when compared with women receiving cerclage alone," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Doctors Urged to Speak With Patients About Firearms

Doctors Urged to Speak With Patients About Firearms

Making a public commitment is encouraged as a positive action that physicians can take

Machine Learning Model Predicts Risk of Upgrade to Breast CA

Machine Learning Model Predicts Risk of Upgrade to ...

Model can predict risk of upgrade of high-risk breast lesions to cancer using traditional, text features

Glycemic Control Up With Oral Semaglutide in Type 2 Diabetes

Glycemic Control Up With Oral Semaglutide in Type ...

Phase 3 studies next to assess longer-term/clinical outcomes, safety

is free, fast, and customized just for you!

Already a member?

Sign In Now »